

JAMES M. PELLISSIER
180 BAYSIDE DRIVE, EASTHAM MA 02642

630 569-0067

JPELLISSIER@COMCAST.NET

SENIOR-LEVEL HEALTH ECONOMICS, OUTCOMES RESEARCH, MARKET ACCESS

PROFESSIONAL PROFILE

- High integrity, high-performing executive with expertise in development, conduct, and interpretation of health economic models, analyses, statistical and outcomes research to communicate the value of drugs and vaccines for decision-making across the development life cycle to decision-makers and stakeholders
- Creative thinker with the ability to solve problems and approach issues with novel thinking
- Persuasive communicator with strong oral and written communications skills, effective organizational skills and the ability to powerfully present ideas to a wide variety of audiences
- Seasoned, pragmatic strategist with a keen understanding of the scientific, business, cultural and market dynamics that shape effective applied value-evidence strategies
- Practiced user of data analytics to inform strategies, with a strong working knowledge of primary research design from a business perspective
- Experienced leader, manager and motivator of cross-functional teams with demonstrated ability to achieve stated objectives
- Productive researcher, with extensive publication record in both methodological and applied research
- Proficient collaborator across a variety of healthcare systems and environments, both in the United States and abroad
 - Lead teams that have developed de novo global economic models, analyses and economic sections for AMCP and HTA submissions
 - Interact directly with US public advisory agencies such as ACIP and independent organizations such as ICER
 - Record of successful interactions and submissions in multiple disease areas with ex-US Health Technology Assessment (HTA) agencies spanning the globe, including NICE (UK), pCODR (Canada), PBAC (Australia), HAS (France), TLV (Sweden) and HIRA (Korea)
- Influential provider of insights that help shape global and regional pricing strategies

AREAS OF EXPERTISE

- | | | |
|---|--|---|
| <ul style="list-style-type: none">• Health Economic Modeling<ul style="list-style-type: none">○ Cost-effectiveness○ Budget impact○ Cost-consequence○ Burden of disease• Strategic Planning• Management of Scientists• Data visualization and communication• Utility elicitation and analyses• Decision Analysis | <ul style="list-style-type: none">• Project Management• Health Technology Assessment• Quality of life analyses• Multi-disciplinary collaborative research• Statistical analyses• Indirect Treatment Comparison• Value frameworks• Survival analysis• Simulation• Industrial/Process Engineering | <ul style="list-style-type: none">• Training and education• Clinical trial analyses• Outcomes research• Resource management• Quality control• Operations Research/Optimization• Discrete modeling• Continuous-time modeling• Time-motion study• Stochastic tree modeling |
|---|--|---|

PROFESSIONAL EXPERIENCE

Self-Employed

Consultant

2021-Present

- *Providing strategic planning, high-level health economic study & modeling design and feasibility assessment of real-world evidence for projects across multiple geographies and therapeutic areas.*

<p>Merck Research Laboratories Center for Observational and Real-World Evidence (CORE) Upper Gwynedd, PA</p>	<p>Executive Director Economic and Data Sciences</p>	<p>2012-2021</p>
<ul style="list-style-type: none"> • <i>Lead health economic support for Merck's Oncology Franchise with work ranging from the planning and performance of health economic evidence generation, modeling and analyses for drugs or vaccines in the pre-approval development phases through post-approval reimbursement and pricing efforts.</i> • <i>Oversaw health economic modeling and evidence generation across successful global Keytruda® launches, e.g. melanoma, non-small cell lung cancer, bladder cancer, head and neck cancer, classical Hodgkin's lymphoma and MSI-high tumor agnostic cancers</i> • <i>Ensured agile, insightful planning and launch readiness for additional forthcoming Merck Oncology and partnership indications across Oncology portfolio (Keytruda®, combinations with axitinib, Lenvima® and Lynparza®). This was accomplished through methodological and process advancement as well as innovative models and communication platforms</i> • <i>Managed a group of 18 health economists and statisticians with additional extended supporting staff</i> • <i>As member of lead team, engineered transformational evolution in departmental business model that enables fulfillment of effective deliverables amidst unprecedented demand and accelerated timelines, while maintaining recognized high-quality models and analyses</i> • <i>Led cross-functional global team to create Merck standard operating procedure for development of health economic models and their adaptations. The resulting industry-leading approach was implemented globally within Merck and its subsidiaries as well with vendors working with Merck and MSD.</i> 		
<p>Merck Research Laboratories Biostatistics and Research Decision- Sciences (BARDS), Upper Gwynedd PA</p>	<p>Senior Director Health Economic Statistics</p>	<p>2011-2012</p>
<ul style="list-style-type: none"> • <i>Responsible for provision of health economic support for the Neurosciences/Ophthalmology, Women's Health BRID (Bone, Respiratory, Immunology and Dermatology) and Oncology franchises</i> • <i>Managerial responsibility for four direct reports</i> 		
<p>Merck Research Laboratories BARDS, Upper Gwynedd, PA</p>	<p>Director Health Economic Statistics</p>	<p>2004-2010</p>
<ul style="list-style-type: none"> • <i>Responsible for execution and delivery of health economic support for the portfolio of projects in Neurosciences/Ophthalmology, Women's Health, Bone, Respiratory, Immunology, Dermatology, and Oncology</i> • <i>Functional area matrix managerial responsibility for four direct reports</i> • <i>Led health economic support for zoster vaccine. First industry-based health economist invited to present work at full ACIP.</i> • <i>Met the challenge of integrating the additional portfolio of work associated with legacy Schering-Plough products and projects post merger. This required rapid, rigorous scientific and business evaluation, diplomacy, creative resourcing and thoughtful implementation</i> 		
<p>Merck Research Laboratories BARDS, Upper Gwynedd, PA</p>	<p>Associate Director Health Economic Statistics</p>	<p>2000-2004</p>
<ul style="list-style-type: none"> • <i>Led health economic support across a broad variety of disease areas, including arthritis, Alzheimer's Disease, cancer chemoprevention, depression, chemotherapy-induced nausea/vomiting, sleep disorder, glaucoma, combination vaccines, hepatitis B vaccination and herpes zoster</i> 		
<p>Merck Research Laboratories BARDS, Blue Bell, PA</p>	<p>Sr. Biometrician Health Economic Statistics</p>	<p>1996-2000</p>
<ul style="list-style-type: none"> • <i>Led health economic support for combination vaccines, herpes zoster, hepatitis B, osteoarthritis, rheumatoid arthritis, urinary incontinence, sarcopenia and benign prostatic hyperplasia</i> 		
<p>Loyola University Chicago Management Science Department School of Business Administration Chicago IL</p>	<p>Associate Professor Assistant Professor Instructor</p>	<p>Promotion to Associate Professor and Tenure awarded, 1996 1990-1996 1988-1990</p>
<ul style="list-style-type: none"> • <i>While maintaining an active research agenda focusing on applications of decision-analysis to medical treatment decisions, taught a broad portfolio of undergraduate and graduate courses. Classes taught included statistics and data analysis, management science, Microsoft Excel, productivity and time-motion study, operations management, and project management</i> • <i>Advisor to Management Science Club</i> 		
<p>United Parcel Service National Operations Group Greenwich CT</p>	<p>Industrial Engineer</p>	<p>1987</p>
<ul style="list-style-type: none"> • <i>Developed and implemented Box-Jenkins forecasting models of call-center demand, enabling more efficient staffing and resourcing solutions</i> 		

Archdiocese of Chicago, Chicago IL **Consultant** **1986**

- *Using multi-criteria decision-analysis, provided quantified recommendation for selection of central computer system using criteria, values and weights derived from Archdiocesan decision-makers*

Industrial Engineering and Management Science Department **Research and Teaching Assistant** **1985-1988**
Northwestern University, Evanston IL

EDUCATION

<u>Institution</u>	<u>Date</u>	<u>Major/Minor Courses</u>	<u>Degree</u>
Northern Illinois University	2006	Elementary Education	M.E.E.
Northwestern University	1991	Industrial Engineering & Management Science Dissertation: "Continuous-risk Utility Assessment in Medical Decision-making"	Ph.D.
Northwestern University	1986	Systems-Management Science	M.S.
University of Miami	1984	Systems Analysis	B.S.

PUBLICATIONS

1. Huang M, Ramsey S, Xue W, Xie, J, Pellissier JM, Briggs A. Conceptual framework and methodological challenges for modeling effectiveness in oncology treatment sequence models. *Pharmacoeconomics*, 2022 40:257-268.
2. Huang M, Pietanza C, Samkari A, Pellissier, J, Burke T, Chandwani S, Kong F, Pickard S. Q-TWiST analysis to assess benefit-risk of pembrolizumab in PD-L1-positive advanced or metastatic non-small cell lung cancer. *Pharmacoeconomics*, 2019 37(1): 105-116.
3. Srivastava, T; Prabhu VS, Li H, Xu R, Zarabi N, Zhong Y, Pellissier JM, Perini RF, R. d. Wit R, Mamtani R. Cost-effectiveness of pembrolizumab in the treatment of second-line Therapy for the Treatment of Locally-Advanced or Metastatic-Urothelial Carcinoma in Sweden. Forthcoming in *European Urology Oncology*. Published online Nov. 22, 2018: [https://euoncology.europeanurology.com/article/S2588-9311\(18\)30172-X/fulltext](https://euoncology.europeanurology.com/article/S2588-9311(18)30172-X/fulltext)
4. Patterson K, Prabhu VS, Xu R, Li H, Meng Y, Zarabi N, Zhong Y, Batterson R, Pellissier JM, Keefe S, Grivas P, de Wit R. Cost-effectiveness of pembrolizumab for patients with advanced, unresectable or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Forthcoming in *European Urology Oncology*. Published online Nov. 8 2018: [https://euoncology.europeanurology.com/article/S2588-9311\(18\)30169-X/fulltext](https://euoncology.europeanurology.com/article/S2588-9311(18)30169-X/fulltext)
5. Miguel, LS, Lopes, FV, Pinheiro B, Wang, J, Xu R, Pellissier J and Laires PA. Cost-effectiveness of pembrolizumab for advanced melanoma treatment in Portugal, *Value in Health*, 2017 20(8): 1065-73.
6. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R and Velcheti V. "Cost-effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for advanced NSCLC that expresses high levels of PD-L1 in the United States," *Pharmacoeconomics*, 2017 Aug 35(8): 831-44.
7. Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, and Liu FX. Cost-effectiveness of pembrolizumab versus ipilimumab in ipilimumab-naïve patients with advanced melanoma in the US. *Journal of Managed Care & Specialty Pharmacy*, 2017 Feb 23(2): 184-194.
8. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. *J Med Econ*. 2016 Oct 3:1-11.
9. Green Park Collaborative Advisory Panel. Best Practices for the Design, Implementation, Analysis, and Reporting of Oncology Trials with High Rates of Treatment Switching, October 2016 v1.0; http://www.cmtynet.org/docs/resources/Treatment_Switching_Guidance_Document_OCT_2016.pdf
10. Jönsson L, Justo N, Musayev A, Krishna A, Burke T, Pellissier J, Judson I, Staddon A, Blay JY. Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy: The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. *Eur J Cancer Care (Engl)*. 2016 May; 25(3):466-477.
11. Li X, Zhang JH, Betts RF, Morrison VA, Xu R, Itzler RF, Acosta CJ, Dasbach EJ, Pellissier JM, Johnson GR, Chan IS. Modeling the durability of Zostavax® vaccine efficacy in people ≥60 years of age. *Vaccine*. 2015 Mar 17;33(12):1499-1505.
12. Chan SL, Jen J, Burke T, Pellissier J. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. *Asia Pac J Clin Oncol*. 2014 Mar;10(1):80-91.
13. Lopes G, Burke T, Pellissier JM, Zhang XH, Dedhiya S, and Chan A. "Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore." *Value in Health Regional Issues* 2012,1(1): 66-74.
14. Singhal PK, Makin C, Pellissier JM, Sy L, White RR, Saddier P. Work and productivity loss related to herpes zoster. *J Med Econ.*, 2011,14(5): 639-645.
15. Yawn BP, Itzler RF, Wollan P, Pellissier J, Sy LS, Saddier P. Healthcare utilization and cost burden of herpes zoster in a community population, *Mayo Clinic Proceedings*, 2009; 84(9): 787-794.
16. White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Incremental one-year medical resource utilization and costs for patients with herpes zoster in a set of United States health plans. *Pharmacoeconomics* 2009; 27(9) 781-792.
17. Wilson SE, Turpin RS, Kumar RN, Itani KM, Jensen EH, Pellissier JM, Abramson MA. Comparative cost of ertapenem and cefotetan as prophylaxis for elective colorectal surgery. *Surgical Infections* 2008; 9(3): 349-356.

18. Brisson M, Pellissier JM, Camden S, Quach C De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. *Human Vaccines* 2008; 4(3): 65-72.
19. Brisson M, Pellissier JM, Levin, MJ. Letter to the Editor— Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against PHN. *Clinical Infectious Diseases* 45, 2007, p. 1527-1529.
20. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and post-herpetic neuralgia in older adults. *Vaccine* 25(49): 2007, p. 8326-8337.
21. Jansen JP, Pellissier JM, Choy EH, Ostor A, Nash JT, Bacon P and Hunsche E. "Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the U.K. *Current Medical Research and Opinion* 23, 12:2007 p.2069-3078.
22. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: Healthcare resource utilization and costs in a group of US health plans. *Pharmacoeconomics* 2007; 25(2): 155-169.
23. Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier JM, Davies GM, Deuson R. "Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany," *European Journal of Cancer* 43(2):2007 p.299-307.
24. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. *Journal of General Internal Medicine* 2005; 20(8): 748-753
25. Pellissier JM; Watson DJ; Kong SX; and Straus WL. Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis, *Ann Intern Med* 2004 140(9) 761-763.
26. Schnitzer TJ, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis, *Clinical Therapeutics* 2003. 25: 3162-3172.
27. Moore RA, Pellissier JM, Phillips CJ, and Kong SX. Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom, *Journal of Drug Assessment* 4, 1:21-37; 2001.
28. Pellissier JM, Straus WL, Watson DJ, Kong SX and Harper S, Economic evaluation of rofecoxib versus non-selective non-steroidal anti-inflammatory drugs for osteoarthritis, *Clinical Therapeutics* 23; 7:1061-1079; 2001.
29. Ruchlin HS, Pellissier JM, An economic overview of prostate cancer, *Cancer* 92; 11: 2796-2810; 2001.
30. Marshall JK, Pellissier JM, Attard CL, Belfry, L., Marentette M, Sauvageau C and Kong SX. Incremental Cost-Effectiveness Analysis Comparing Rofecoxib to Non-Selective NSAIDs in the Treatment of Osteoarthritis, *Pharmacoeconomics* 19; 10:1039-1049; 2001.
31. Rahme E, Joseph L, Kong SX, Watson DJ, Pellissier JM, and J LeLorier. Gastrointestinal-related adverse events associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs, *Pharmacoeconomics* 19, 5 pt. 2:577-588; 2001.
32. Moore RA, Pellissier JM, Phillips CJ, and Kong SX. Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom, *Journal of Medical Economics* 4, 1:1-17; 2001.
33. Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM and Fitzsimon C. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents in the United States, *Pediatrics* 108, 2, p. 317-325, 2001.
34. Pellissier JM, Coplan P, Jackson L, and May J. The effect of additional shots on the vaccine administration process: Results of a time-motion study in two settings, *American Journal of Managed Care* 6, 9: 41-47, 2000.
35. Gottlob CA, Baker CL, and Pellissier JM. Long-term cost-effectiveness of ACL reconstruction in young adults, *Clinical Orthopedics and Related Research*, 367, 10:272-282, 1999.
36. Albertsen P, Pellissier JM, Lowe F, Girman CJ and Roehrborn C. Economic analysis of finasteride: A model-based approach using data from the Proscar Long-Term Efficacy and Safety Study, *Clinical Therapeutics*, 21, 6:1006-1024, 1999.

37. Copley-Merriman K, Vanscoy G, Pellissier JM, Schultz R, Draugalis JR, Freund D, Penna P, Beis S. and Angaran D. Education and skills needed to conduct, interpret and use economic evaluations in healthcare, *Value in Health* 2, 2:88-91, 1999.
38. Hazen GB, Pellissier JM, and Sounderpandian J. Stochastic tree models in medical decision-making, *Interfaces* 28:4, 1998.
39. Chang RW, Pellissier JM. Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip, *JAMA*, 275, 11:858-865, 1996.
40. Hazen GB and Pellissier JM. Recursive utility for stochastic trees, *Operations Research*, 44, 5:788-809, 1996.
41. Pellissier JM, Hazen GB, and Chang RW. A continuous-risk decision analysis of total hip replacement, *Journal of the Operational Research Society*, 47, 6:776-793, 1996.
42. Pellissier JM and Van Buer MG. Entrepreneurial proclivity and the interpretation of subjective probability phrases, *Journal of Applied Business Research*, 12, 4:129-137, 1996.
43. Venta ER and Pellissier JM. Introducing patient values into the decision making process for breast cancer screening policies, *Women and Health*, 24, 4:46-67, 1996.
44. Levine DM, Berenson ML, Pellissier JM, Stephan D. *Statistics for Managers Using Microsoft Excel*, Prentice-Hall, Englewood Cliffs, NJ, 1997.
45. Levine DM, Berenson ML, Pellissier JM. *Student Lecture Notes*, Prentice-Hall, Englewood Cliffs, NJ, 1997.
46. Pellissier JM. *Exploring Data Using Microsoft Excel 5.0*, Prentice-Hall, Englewood Cliffs, NJ, 1995.
47. Pellissier JM and Hazen GB. Implementation of continuous-risk utility assessment: The total hip replacement decision, *Socio-Economic Planning Sciences*, 28, 4:251-276, 1994.
48. Hazen GB, Hopp WJ, and Pellissier JM. Continuous-risk utility assessment in medical decision-making, *Medical Decision Making*, 11, 4:294-304, 1991.

CONFERENCE AND MAJOR PROFESSIONAL PRESENTATIONS

1. Ramsey S, Pellissier J, Huang M, Briggs A. Choices amidst the choices – Assessing treatment sequences in oncology. Health Technology Assessment International (HTAi) 2020 Annual Meeting (Virtual). November 10, 2020.
2. Pellissier JM. Questions as answers? Examination of the value of economic models throughout the drug/vaccine development lifecycle. Center for Pharmacoepidemiology & Pharmacoeconomic Research Health Outcomes Seminar Series, University of Illinois, Chicago. Invited speaker. Chicago, IL. October 15, 2020
3. Pellissier J. Modeling the impact of multi-indication innovations on health and budget. B. Braun Symposium. Invited speaker. Berlin, Germany. June 4, 2019.
4. Zhong Y, Li H, He J, Lai Y, Pellissier J. Pattern of disease management costs for advanced bladder cancer patients. AMCP Managed Care and Specialty Pharmacy Annual Meeting, San Diego, CA. March 25-28 2019.
5. Huang M, Pellissier J, Chandwani S, Insinga R, Burke T, Pickard S. Health state utilities in metastatic NSCLC: A study of multiple immuno-oncology trials. Forthcoming at ISPOR-EU 2018, 21st Annual European Congress. Barcelona, Spain, November 10-14, 2018.
6. Huang M, Pietanza C, Samkari A, Pellissier, J, Burke T, Chandwani S, Kong F, Pickard S. A Q-TWiST analysis of pembrolizumab in PD-L1-positive metastatic NSCLC. Forthcoming at European Society for Medical Oncology (ESMO) Annual Meeting, Munich, Germany, Oct 19-23.
7. Van Bavel J, Lucherini S, Spandonaro F, Polistena B, Dirodi B, Eterno V, Didoni G, Davies N, Pellissier JM, and Roediger A. Budget and health impact of immune-oncology treatments in Italy. Forthcoming at ISPOR-EU 2018, 21st Annual European Congress. Barcelona, Spain, November 10-14, 2018.
8. Van Bavel J, Lucherini S, Davies N, Okhua P, Pellissier JM, and Roediger A. Projecting the budget and health impact of PD-1/PD-L1 inhibitors to inform budget planning. Forthcoming at 11th European Public Health Conference, Ljubljana, Slovenia, Nov 28-Dec 1, 2018.

9. Van Bavel J, Lucherini S, Zielinski C, Walter E, Eckart G, Davies N, Okhua P, Pellissier JM, and Roediger A. Budget and health impact of PD-1/PD-L1 inhibitors class in Austria. Forthcoming at 11th European Public Health Conference, Ljubljana, Slovenia, Nov 28-Dec 1, 2018..
10. Van Bavel J, Lucherini S, Rajer M, Derviskadic Jovanovic S, Krizaj Z, Burnik T, Davies N, Toghianian S, Pellissier JM, and Roediger A. Budget and health impact of PD-1/PD-L1 inhibitors class in Slovenia. Forthcoming at 11th European Public Health Conference, Ljubljana, Slovenia, Nov 28-Dec 1, 2018.
11. Van Bavel J, Lucherini S, Vermeersch S, Bento Abreu A, Davies N, Okhua P, Pellissier JM, and Roediger A. Assessing the impact of PD-1/PD-L1 inhibitors on health and budget in Belgium. Forthcoming at 11th European Public Health Conference, Ljubljana, Slovenia, Nov 28-Dec 1, 2018.
12. Pellissier JM, Wu E, Normand R, Bellanca L, Hughes R and Ratcliffe A. A contextual model for evaluation the value of multi-indication drugs. Health Technology Assessment International (HTAi) 2018 Annual Meeting, Vancouver, British Columbia, Canada, June 3, 2018.
13. Wu E, Pellissier JM, Kvamme M, and Irgens K. A holistic approach to evaluate the cost-effectiveness of pembrolizumab with multiple indications: A Norway-based example. Value Health 19[3], A154. ISPOR 23rd International Meeting, Baltimore, MD, May 22, 2018.
14. Pellissier JM. Challenges and Frontiers in Economic Modeling of Immuno-oncology Drugs. ISPOR Latin American Meeting, Mexico City, Mexico. March 10, 2018.
15. Huang, M, Pellissier, J, and Kong, F. A trial-based EuroQol EQ-5D health utility analysis in patients with previously untreated metastatic NSCLC. 22nd Annual ISPOR International Meeting. Boston, MA, May 20-24, 2017.
16. Huang, M, Pellissier, J, and Liao, J. Healthcare resource utilization in patients receiving pembrolizumab or standard-of-care chemotherapy with previously untreated metastatic NSCLC. NCCN 22nd Annual Conference, Orlando FL, March 23-25, 2017.
17. Huang, M, Lou, Y, Pellissier, J, Burke, T, Liu, FX, Xu, R and Velcheti, V. Cost-effectiveness of pembrolizumab versus standard-of-care chemotherapy in first-line treatment of PD-L1 positive metastatic NSCLC patients in the U.S. NCCN 22nd Annual Conference, Orlando FL, March 23-25, 2017.
18. Blank C, Ma J, Grob J, Dummer RC, Schachter J, Pavlick AC, Schadendorf D, Hamid O, Daud A, Hodi FS, Gonzalez R, Johnson DB, Pellissier JM, Wang J, Xu R, Zhang J, Ibrahim N, Ribas A. Adjusting overall survival when accounting for treatment switch in the KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory advanced melanoma. The Society for Melanoma Research (SMR) 2016 Congress, Boston, Massachusetts, November 6, 2016.
19. Huang, M, Pellissier, J and Liao, J. Healthcare resource utilization in patients receiving pembrolizumab or docetaxel with previously treated advanced NSCLC. *Value in Health* 19[7], A755. ISPOR-EU 2016, 19th Annual European Congress. Vienna, Austria, November 1, 2016.
20. Huang, M, Pellissier, J, and Liao, J. A trial-based EuroQol EQ-5D health utility analysis in patients with previously treated advanced NSCLC. Value Health 19[7], A744. ISPOR-EU 2016, 19th Annual European Congress. Vienna, Austria, November 1, 2016.
21. Huang, M, Lou, Y, Pellissier, J, Burke, T, Liu, FX, Xu, R, and Velcheti, V. Cost-effectiveness of pembrolizumab vs. docetaxel for treatment of previously treated PD-L1 positive advanced NSCLC. *Value in Health* 19[7], A737. ISPOR-EU 2016, 19th Annual European Congress. Vienna, Austria, November 1, 2016.
22. Miguel, LS, Lopes, FV, Pinheiro B, Wang, J, Xu R, Pellissier J and Laires PA. Cost-Effectiveness of Pembrolizumab for advanced melanoma treatment in Portugal, ISPOR-EU 2016, 19th Annual European Congress. Vienna, Austria, November 1, 2016.
23. Miguel, LS, Lopes, FV, Pinheiro B, Wang, J, Xu R, Pellissier J and Laires PA. Cost-Effectiveness of Pembrolizumab for patients with advanced melanoma previously treated with ipilimumab in Portugal, ISPOR-EU 2016, 19th Annual European Congress. Vienna, Austria, November 1, 2016.
24. Huang M, Pellissier J, Burke T, Xu R. Implications of Implementation of a PD-L1 Biomarker- based Strategy for Treatment of Advanced NSCLC. IASLC 17th World Conference on Lung Cancer. Vienna, Austria December 4, 2016.

25. Huang, M, Lou, Y, Pellissier, J, Burke T, Liu F and Velcheti V. Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC. IASLC 17th World Conference on Lung Cancer. Vienna, Austria December 4, 2016.
26. Loong, H, Wong C, Leung L, CHOI C, Wang J, Pellissier JM and Stevinson, K. Cost-effectiveness of pembrolizumab (Pembro) compared to ipilimumab (Ipi) or dacarbazine (DTIC) as a first line (1L) treatment for patients with advanced melanoma treated in Hong Kong. European Society for Medical Oncology (ESMO) Asia Congress, Singapore, December 16, 2016.
27. Wang J, Pellissier, J, Xu, R, Liu, F. X., Stevinson, K, and Chmielowski, B. Cost-effectiveness of pembrolizumab (Keytruda®) versus ipilimumab in patients with advanced melanoma in US. Value Health 19[3], A154. ISPOR 21st International Meeting, Washington DC, May 1, 2016.
28. Wang J, Chabot I, El-Hadi W, Xu, R, Pellissier, J, and Iliopoulos, I. Cost-effectiveness of pembrolizumab (Keytruda®) versus ipilimumab in patients with advanced melanoma in Canada. Value Health 19[3], A153. ISPOR 21st International Meeting, Washington DC, May 1, 2016.
29. Xu, R, Wang J, and Pellissier, J. Implementation of a 2-stage crossover correction in analysis of overall survival (OS): An example in oncology. Eastern North American Region (ENAR) International Biometric Society 2016, Spring Meeting, Austin, TX, March 6, 2016.
30. Zhuo, J, Wu E, Dasbach EJ, and Pellissier, J. Cancer associated medical spending: US national data between 2000 and 2013. Value Health 19[7], A742. ISPOR EU 2016, 19th Annual European Congress. Vienna, Austria November 1, 2016.
31. Marriott E, Praet C, Aguiar-Ibáñez R, Pellissier J, Xu R, Wang J. Cost-effectiveness of pembrolizumab for unresectable metastatic melanoma after progression with ipilimumab in England. Value Health. 2015 Nov;18(7):A453. ISPOR EU 2015, 18th Annual European Congress. Milan, Italy.
32. Wang J, Xu R, Anderson K and Pellissier J. Making the most of limited data with uncertainty using probabilistic analyses: A case study in oncology. 35th Annual Meeting of the Society for Medical Decision Making, Baltimore MD, October 23, 2013.
33. Humphries S, Pellissier JM, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. MASCC/ISOO International Symposium on Supportive Care in Cancer, Berlin, Germany, June 27-29, 2013.
34. Xu R, Dasbach EJ, Pellissier JM, Li X, Chan ISF. The cost effectiveness of Zostavax in the United States for adults 50 to 59 years of age. Immunization 45th Annual National Conference, Washington, DC, March 28-31, 2011.
35. Li X, Zhang J, Xu R, Dasbach EJ, Pellissier JM, Johnson GR, Chan ISF. The durability of vaccine efficacy afforded by zostavax. Accepted for presentation at: Society Of Clinical Trials Meeting, Vancouver, British Columbia, May 15-18, 2011.
36. Li X, Zhang J, Xu R, Dasbach EJ, Pellissier JM, Johnson GR, Chan ISF. The durability of vaccine efficacy afforded by zostavax. For presentation at: Immunization 45th Annual National Conference, Washington, DC, March 28-31, 2011.
37. Bridges J, Taylor SD, Arden N, Hauber AB, Johnson R, Watson DJ, Mavros PG, Pellissier JM, Peloso PM, Sen SS, Mohamed A, Gonzalez JM. Preferences over benefits and risks associated with the use of NSAIDs: evidence from patients diagnosed with osteoarthritis (OA) in UK. International Society for Pharmacoeconomics And Outcomes Research 13th Annual European Conference (ISPOR), Prague, Czech Republic, November 6-9, 2010.
38. Bridges J, Taylor SD, Arden N, Hauber AB, Johnson FR, Watson DJ, Mavros PG, Pellissier JM, Peloso PM, Sen SS, Mohamed A, Gonzalez JM. Physicians' stated preferences over benefits and risks associated with NSAID use in patients with osteoarthritis in UK. International Society for Pharmacoeconomics And Outcomes Research 13th Annual European Conference (ISPOR), Prague, Czech Republic, November 6-9, 2010.
39. Wang J, Charos A, Caputo J, Hu, XH, Pellissier JM. Cost-effectiveness analysis of preservative free tafluprost in the treatment of glaucoma and ocular hypertension. European Glaucoma Society Annual Meeting, Madrid, Spain, September 12-17, 2010.
40. Stein AN, Conway EL, Pellissier JM, Senecal M, Cunningham A. Cost effectiveness of herpes zoster vaccination in an Australian National Immunisation Program. 11th National Immunisation Meeting of the Public Health Association of Australia. Gold Coast, Queensland, Australia, September 16-18, 2008.

41. White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Use of claims data to assess the resource utilization and costs of herpes zoster in the first year after diagnosis. Health Policy Statistics 7th International Conference, Philadelphia, Pennsylvania, January 18, 2008.
42. Pellissier JM, Itzler RF, Davies GM. Building an understanding of the economics of a new vaccine through the use of clinical trial and non-clinical trial data: the case of the zoster vaccine. Health Policy Statistics 7th International Conference, Philadelphia, Pennsylvania, January 18, 2008.
43. Pellissier JM. A life-cycle examination of the potential influence of cost-effectiveness modeling in health technology development. Decision Analysis Affinity Group 2008 Conference, Baltimore, Maryland, April 16, 2008.
44. Itzler RF, Pellissier JM, Saddier P, Yawn B, Wollan P. Use of chart abstractions based on review of medical records to assess the healthcare resource utilization and costs of herpes zoster. Health Policy Statistics 7th International Conference, Philadelphia, Pennsylvania, January 18, 2008.
45. Insinga RP, Itzler RF, Pellissier JM. Analysis of Claims Data to Assess Resource Utilization and Costs Using Herpes Zoster as an Example. 7th International Conference on Health Policy Statistics, Philadelphia, Pennsylvania, January 17-18, 2008.
46. Pellissier JM. Understanding Zostavax® Cost-Effectiveness: A Model-Based Approach. Zostavax Internal Medicine, Infectious Disease Advisory Board Meeting, Arlington, VA, November 14, 2007.
47. Pellissier JM. Understanding Zostavax® Cost-Effectiveness. Long-term Care Expert Input Forum, Philadelphia, PA, August 21, 2007.
48. Pellissier JM. "Health Economic Rationale for Zostavax® Pricing," Presentation to Dr. J. Abramson, Chair of ACIP. February 13, 2006.
49. Pellissier JM, Insinga RP, Itzler R, Saddier P, Sy L, Nikas A, White R, Singhal P. "Understanding the Health and Economic Burden of Herpes Zoster," Presentation to ACIP Shingles Working Group, February 14, 2006.
50. Pellissier JM. "A Model-Based Approach to Understanding Zostavax® Cost-Effectiveness," ACIP Shingles Working Group Meeting. April 3, 2006;
51. Pellissier JM. "A Model-Based Approach to Understanding Zostavax® Cost-Effectiveness," Presentation to Multispecialty Advisory Board. April 11, 2006.
52. Pellissier JM. "Evaluation of the Cost-Effectiveness in the U.S. of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults," Presentation to VA Public Health Department, May 22, 2006.
53. Pellissier JM. "Evaluation of the Cost-Effectiveness in the U.S. of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults: An Update," Presentation to ACIP Shingles Working Group. June 19, 2006.
54. Pellissier JM. "Evaluation of the Cost-Effectiveness in the U.S. of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults," Advisory Committee on Immunization Practices Meeting, Atlanta, GA. June 30, 2006.
55. Pellissier JM. "Elements of Zostavax® Cost-Effectiveness," Medical Affairs Director Meeting, Philadelphia PA, August 22, 2006.
56. Pellissier JM. "Discussion of Recent Zoster Vaccine Cost-effectiveness Publication: Comparison to Merck and ACIP Model-based Results," ACIP Shingles Working Group Conference," October 16, 2006; reprise: Meeting with Dr. J. Abramson, Chair of ACIP, October 24, 2006.
57. Pellissier JM. "Review of Zostavax® Efficacy and Durability Modeling Used in Cost-Effectiveness Analyses of the Vaccine," Australian Technical Advisory Group on Immunisation," Sydney, Australia, November 16, 2006.
58. Pellissier JM. "Analyzing Zostavax® Cost-Effectiveness," National Centre for Immunization Research and Surveillance Varicella Zoster Virus Workshop, Sydney, Australia, November 17, 2006.
59. Pellissier JM, "Toward Understanding Zostavax® Cost-Effectiveness in Various Countries: A Model-Based Approach with Examples," Melbourne School of Public Health, Melbourne, Australia, November 13, 2006.
60. Pellissier JM, "Toward an Understanding of Zostavax® Cost-Effectiveness in Australia," Meeting with Dr. Tony Cunningham, Chair of CSL and Zostavax Advisory Board, Sydney Australia, November 16, 2006.

61. White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Annual healthcare costs of shingles (herpes zoster) and its complications. 12th International Congress on Infectious Diseases, Lisbon Portugal, June 17, 2006
62. Singhal PK, McNally D, Saddier P, Pellissier JM, White RR, Segraves AW. Incidence of herpes zoster (shingles) in Medicare population. National Foundation for Infectious Diseases Vaccine Research 9th Annual Conference, Baltimore, Maryland, May 8-May 10, 2006.
63. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the U.S. of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. National Foundation for Infectious Diseases Vaccine Research 9th Annual Conference, Baltimore, Maryland, May 8-10, 2006.
64. Saddier P, Yawn BP, Wollan P, Kurland M, Sy LS, Pellissier JM, Itzler RF. Herpes zoster epidemiology and associated health care use in Olmsted County, MN, USA. Pharmacoepidemiology And Therapeutic Risk Management 22nd International Conference, Lisbon, Portugal, August 24-27, 2006.
65. Jansen, JP, Gaugris S, Choy E, Ostor A, Nash JT, Bacon P, Pellissier JM. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. Asia Pacific League Of Associations For Rheumatology 12th Biennial Congress (APLAR), Kuala Lumpur, Malaysia, August 1-5, 2006.
66. Insinga RP, Itzler RF, Pellissier JM. Healthcare resource utilization and costs of acute/subacute herpes zoster. British Pain Society Annual Scientific Meeting, Harrogate, U.K., April 24-27, 2006
67. Itzler RF, Pellissier JM, Davies GM, Carides GW, Cook JR, Schmader KS. Zostavax® reduces healthcare encounters for herpes zoster (HZ). Infectious Disease Society of America 44th Annual Meeting. Toronto, Canada, Oct 12-15, 2006.
68. Chen Y., Pellissier JM, Kumar RN, Hu XH, Gan TJ. Economic analysis of aprepitant and ondansetron for the prevention of postoperative vomiting. American Society of Anesthesiology 2006 Annual Meeting, Chicago, Illinois, October 14-18, 2006.
69. Brisson M, Pellissier JM, Levin MJ, Quach C, De Wals P. Potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia in Canada. Infectious Diseases Society of America 44th Annual Meeting (IDSA), Toronto, Canada, October 12-14, 2006.
70. Pellissier JM, Hunsche E, Chisholm C, Urdahl HF, Phillips CJ. Evaluation of the cost-effectiveness of etoricoxib in the treatment of OA/RA in the UK. European League Against Rheumatism 6th Annual Congress (EULAR), Vienna, Austria, June 8-11, 2005.
71. Martin M, Hunsche E, Boice JA, Conaghan P, Pellissier JM. An economic cost analysis of etoricoxib versus indomethacin in the treatment of acute gouty arthritis in the UK. European League Against Rheumatism 6th Annual Congress (EULAR), Vienna, Austria, June 8-11, 2005.
72. Jansen JP, Hunsche E, Choy E, Ostor A, Pellissier JM. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. American College Of Rheumatology 2005 Annual Scientific Meeting (ACR), San Diego, California, November 12-17, 2005.
73. Jansen JP, Hunsche E, Choy E, Ostor A, Nash JT, Bacon P, Pellissier JM. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK. European League Against Rheumatism 6th Annual Congress (EULAR), Vienna, Austria, June 8-11, 2005.
74. Pinto CG, Hunsche E., Rubinsky S, Pellissier JM, Pereira da Silva JA, Miguel LS, Guimarães JP. "Economic evaluation of etoricoxib versus NSAIDs in patients with osteoarthritis in Portugal." Fourth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Nice, France, November 14-17, 2003.
75. Moore A, Phillips C, Hunsche E, Pellissier JM, Kingslake S, Kong SX. "Cost-effectiveness of etoricoxib compared to traditional NSAIDs in the UK." European League Against Rheumatism (EULAR) Conference, Lisbon, Portugal, June 18-21, 2003.
76. Jönsson B, Hunsche E, Pellissier JM, Rubinsky S, Kujala V, Kong SX. "Economic evaluation of etoricoxib versus NSAIDs in patients with osteoarthritis in Finland." European League Against Rheumatism (EULAR) Conference, Lisbon, Portugal, June 18-21, 2003.
77. Itzler R, Choo P, Bauer M, Bulotsky M, Canning C, Coplan P, Nikas A, and Pellissier JM. "Comparison of patient self-reported healthcare resource utilization to electronic record data: Lessons learned from a study of herpes zoster

- patients." 8th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Crystal City, VA, May 18-21, 2003.
78. Schnitzer TJ, Mavros PG, Straus WL, Watson DJ, Pellissier JM and SX Kong. "Rofecoxib is associated with lower rates of concurrent gastroprotective medication use compared to celecoxib." 3rd International Symposium on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Barcelona, Spain, November 6-9, 2002.
 79. Schnitzer TJ, Kong SX, Mitchell J, Mavros PG, Watson DG, Pellissier JM and Straus WL. "Prescription of rofecoxib and celecoxib by physician specialty for patients with osteoarthritis and rheumatoid arthritis." American College of Rheumatology 66th Annual Scientific Meeting, New Orleans, LA, October 26, 2002.
 80. Schnitzer TJ, Mavros PG, Kong SX, Pellissier JM, Mitchell JH, Straus WL, and Watson DJ. "Are selective Cox-2 inhibitors used more frequently in patients at risk of gastrointestinal complications than conventional anti-inflammatory drugs (NSAIDs)?" Pan American League Against Rheumatism (PANLAR) Congress, Aruba, June 23-27, 2002.
 81. Schnitzer TJ, Kong SX, Pellissier JM, Mitchell JH, Mavros P, Watson DJ, and Straus WL. "Use patterns of celecoxib and rofecoxib in the United States." Pan American League Against Rheumatism (PANLAR) Congress, Aruba, June 23-27, 2002.
 82. Schnitzer TJ, Kong SX, Mavros P, Mitchell JH, Straus WL, Watson DJ, and Pellissier JM. "Selective Cox-2 inhibitors vs. non-selective nonsteroidal anti-inflammatory drugs (NSAIDs): Persistency over a 120-day period." Pan American League Against Rheumatism (PANLAR) Congress, Aruba, June 23-27, 2002.
 83. Schnitzer TJ, Mavros PG, Kong SX, Pellissier JM, J. Mitchell J, Straus WL, Watson DJ. "Risk of gastrointestinal adverse events among patients who initiated selective Cox-2 inhibitors vs. conventional nonsteroidal anti-inflammatory drugs (NSAIDs)." European League Against Rheumatism (EULAR) Conference, Stockholm, Sweden, June 12-15, 2002.
 84. Schnitzer TJ, Kong SX, Mavros P, Mitchell JH, Straus WL, Watson DJ, and Pellissier JM. "Persistence of use of selective Cox-2 inhibitors versus nonselective NSAIDs: Analyses of a large pharmacy database in the United States." European League Against Rheumatism (EULAR) Conference, Stockholm, Sweden, June 12-15, 2002.
 85. Attard CL, Pellissier JM, Kong SX, Marentette, M. "Economic implications of treating rheumatoid arthritis patients in Ontario, Canada with rofecoxib versus non-selective NSAIDs," European League Against Rheumatism (EULAR) Conference, Stockholm, Sweden, June 12-15, 2002.
 86. Schnitzer TJ, Kong SX, Pellissier JM, Mitchell JH, Mavros P, Watson DJ and Straus WL. "Average daily consumption of celecoxib and rofecoxib based on a large pharmacy claims database in the United States of America" European League Against Rheumatism (EULAR) Conference, Stockholm, Sweden, June 12-15, 2002.
 87. Levaux HP, Schonfeld WH, Pellissier JM, Cassidy WM, Sheriff, SK and Fitzsimon, C. "Economic evaluation of hepatitis B vaccination in the U.S." National Hepatitis Coordinators' Conference, Richmond, Virginia, July 29, 2001-August 2 2001.
 88. Bombardier C, Carides G, Pellissier JM, Ramey D, Watson D, and Reicin A. "Less healthcare resource utilization for perforations, ulcers and bleeds with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) study," European League Against Rheumatism (EULAR) Conference June 11-16, 2001.
 89. Laine L, Bombardier C, Ramey D, Pellissier JM, Watson D, and Reicin A. "Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the vigor (VIOXX GI Outcomes Research) study," European League Against Rheumatism (EULAR) Conference June 11-16, 2001.
 90. Pellissier JM and Kong, SX. "Health economic evaluation of rofecoxib vs. conventional NSAIDs in the treatment of osteoarthritis in Switzerland," European League Against Rheumatism (EULAR) Conference June 11-16, 2001.
 91. Attard C, Pellissier JM, Kong SX, Marentette M, and Sauvageau C. "Economic analysis of rofecoxib vs. NSAIDs: Comparison across different provinces in Canada," European League Against Rheumatism (EULAR) Conference June 11-16, 2001.
 92. Attard C., Pellissier JM, Belfry L, Kong SX, Marentette M, Sauvageau C. "Economic implications of comparing rofecoxib to non-selective NSAIDs in the treatment of osteoarthritis in Ontario, Canada," European League Against Rheumatism (EULAR) Conference, June 21-24, 2000.
 93. Pellissier JM, Straus WL, Watson DJ, Kong SX. "Exploration of the economic implications of rofecoxib versus NSAIDs: A decision-analytic approach," 23rd Annual Meeting of the Society of General Internal Medicine, Boston, MA, May 4-6, 2000.

94. Albertsen P, Pellissier JM, Lowe F, Girman C, and Roehrborn C for the PLESS Study Group: Economic implications of effects of finasteride on the risk of acute urinary retention and need for surgery. 94th Annual Meeting of the American Urological Association, Dallas, TX, May 1999.
95. Hazen GB, Sounderpandian J, and Pellissier JM: Factored stochastic tree modeling for arthritic joint replacement decisions. 20th Annual Meeting of the Society for Medical Decision Making, Boston, MA, October 1998.
96. Pellissier JM, Coplan PM, Jackson LA, and May J: Time savings from reducing the number of injections in the pediatric vaccination regimen in a managed care setting. 38th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting, San Diego, California, September 1998.
97. Educational and Skills Advisory Panel for Pharmacoeconomics: Identifying the Issues Conference, Crystal City, VA, February 18-20, 1998. Sponsored by International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
98. Pellissier JM, Coplan PM, Jackson LA, and May J "Assessment of time savings by reducing vaccination injections: A time-motion study." 32nd National Immunization Conference, Atlanta, GA, July 21-24, 1998.
99. Pellissier JM, Dasbach EJ, Copley-Merriman, and Murray JF: Pharmacoeconomics From an Industry Perspective. Coordinator and faculty member for short-course at 19th Annual Meeting of the Society for Medical Decision Making, Houston, TX, October 1997.
100. Roehrborn CG, Pellissier JM, Girman CJ, Ben-Joseph R, and Andersen JT: Economic implications of long-term effects of finasteride on occurrence of acute urinary retention and surgical intervention for BPH. 4th International Consultation on BPH, Paris, France, July 1997.
101. Gottlob CA, Baker CL, and Pellissier JM: Long-term cost effectiveness of ACL reconstruction in young adults. American Orthopaedic Society for Sports Medicine Meeting, Sun Valley, Idaho, June 1997.
102. Hazen GB, Sounderpandian J, and Pellissier JM: Factored stochastic trees. INFORMS National Conference, Atlanta, GA, November 1996.
103. Gottlob CA, Baker CL, and Pellissier JM: Impact of sports participation on the general well-being of adults. SEC Sports Symposium, New Orleans, LA, March 8, 1996.
104. Pellissier JM: Analyzing medical decisions using stochastic trees," Invited speaker, Northeastern Illinois Chapter of the American Statistical Association, Northbrook, IL, March 1996.
105. Pellissier JM, Chang RW, and Hazen GB: The implications of new technology on the cost-effectiveness of total joint replacement. 17th Annual Meeting of the Society for Medical Decision Making, Phoenix, AZ, October 1995.
106. Gottlob CA, Pellissier JM, Chang RW, Wixson R, and Stern S: A cost-effectiveness of total knee replacement. American Orthopedic Association Annual Resident's Conference, Pittsburgh, PA, March 1995.
107. Pellissier JM and Hazen GB: Coxian mortality factors for stochastic tree modeling. 16th Annual Meeting of the Society for Medical Decision Making, Cleveland, OH, October 1994.
108. Pellissier JM, Venta ER, and Venta LA: A decision-analytic model of breast cancer screening policies for women aged 40-49. ORSA/TIMS Joint National Meeting, Phoenix, AZ, October 31-November 3, 1993.
109. Pellissier JM, VanBuer MG, and Zydiak JL: The effect of rehabilitation on economic life when utilization matters. ORSA/TIMS Joint National Meeting, Phoenix, AZ, October 31-November 3, 1993.
110. Pellissier JM: Consideration of cost aspects in stochastic tree models of medical treatment decisions. ORSA/TIMS Joint National Meeting, San Francisco, CA, November 1992.
111. Pellissier, JM: A decision model for patients with severe osteoarthritis of the hip. Invited speaker, Northwestern Memorial Hospital Arthritis Center's Meeting on Total Joint Replacement, Chicago, IL, July 1992.
112. Pellissier JM, Hazen GB, and Hopp WJ: Application of continuous risk utility assessment to the total hip replacement decision. ORSA/TIMS Joint National Meeting, Orlando, FL, April 1992.
113. Pellissier JM: Implementation of continuous risk utility assessment: The total hip replacement decision. Invited speaker, Management Science Lecture Series, Northwestern University, Evanston, IL, February 1992.

114. Hazen GB, Pellissier JM, and Hopp WJ: Continuous risk utility assessment in medical decision-making. ORSA/TIMS Joint National Meeting, Anaheim, CA, November 1991.

RESEARCH GRANTS RECEIVED

- “An investigation of technology effects on the cost-effectiveness of total knee replacement,” Loyola University Chicago Summer Research Grant, 1996.
 - “Total hip arthroplasty decision-making: Risk attitudes and values of patients, rheumatologists, and orthopedic surgeons,” with R.W. Chang and G.B. Hazen. Arthritis Foundation, Illinois Chapter Grant, 1994.
 - “A decision-analytic model of breast cancer screening policies for women aged 40-49,” Loyola University Chicago Summer Research Grant, 1994.
 - “Development of a cost-benefit model for the total hip replacement decision,” Loyola University Chicago Summer Research Grant, 1992.
 - “A factor approach to building stochastic tree models for use in medical decision making,” Loyola University Chicago School of Business Administration Summer Research Grant, 1991.
-

SOCIETY MEMBERSHIPS AND CONTRIBUTIONS

- Society for Medical Decision Making
 - Member, Scientific Review Committee for SMDM Annual Meeting (from 1997)
- International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
- American Society of Clinical Oncology (ASCO)
- Served on Educational and Skills Advisory Panel for Pharmacoeconomics: Identifying the Issues Conference, Crystal City, VA, February 18-20, 1998. Sponsored by International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
- Served on PHRMA Biomarker Qualification Statistical Expertise Team (2009)
- Served on PHRMA Working Group on clinical importance of progression-free survival in oncology (2009-10)
- Member of Organizing Committee and Advisory Panel to Green Park Collaborative initiative on guidelines for treatment switching in oncology. 2015-2016.
- Have served as referee for *Medical Decision Making*, *Women and Health*, *American Journal of Managed Care*, *Value in Health*, *Pharmacoeconomics*, *JAMA*, *Interfaces*, *Vaccine*

ACADEMIC AND PROFESSIONAL HONORS

- Research Scholar, Loyola University Chicago (1996-2005)
- Hazen GB, Pellissier JM, and Sounderpandian J: Stochastic tree models in medical decision-making *Interfaces* 28:4, 1998 awarded ANBAR Citation of Excellence, 1998.
- GB Hazen and JM Pellissier, "Recursive utility for stochastic trees," *Operations Research*, 44, 5, 1996, p. 788-809 awarded Institute for Operations Research and Management Science (INFORMS) and Decision Analysis Society's Publication Award for 1996-1997.